keyword
MENU ▼
Read by QxMD icon Read
search

Olumiant

keyword
https://www.readbyqxmd.com/read/30322726/prostate-cancer-in-transgender-women
#1
REVIEW
Matthew D Ingham, Richard J Lee, Dhara MacDermed, Aria F Olumi
INTRODUCTION: As the transgender patient population continues to increase, urologists and other providers who treat genitourinary malignancies will increasingly encounter cases of prostate cancer in transgender women. Little exists in the current literature to help summarize the challenges and opportunities which face this unique patient population. Similarly, little exists to provide guidance on how we may best diagnose, manage, and follow transgender women diagnosed with prostate cancer...
October 12, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/30287224/impact-of-multifocality-and-multilocation-of-positive-surgical-margin-after-radical-prostatectomy-on-predicting-oncological-outcome
#2
Shulin Wu, Sharron X Lin, Gregory J Wirth, Min Lu, Jian Lu, Alexander O Subtelny, Zongwei Wang, Douglas M Dahl, Aria F Olumi, Chin-Lee Wu
OBJECTIVE: To assess the impact of focality and location of positive surgical margins (PSM) on long-term outcomes after radical prostatectomy (RP) for prostate cancer (PCa), including biochemical recurrence (BCR), metastasis and overall mortality. PATIENTS AND METHODS: From a total of 2796 cases of RP between 1993 and 2007 in our single hospital, 476 cases with PSMs were identified and included in this study. PSM location was categorized into apex, peripheral, and bladder neck...
August 30, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/30186023/pharmaceutical-approval-update
#3
Michele B Kaufman
Baricitinib (Olumiant) tablets for rheumatoid arthritis; plazomicin (Zemdri) injection for complicated urinary tract infections; and cannabidiol (Epidiolex) oral solution for seizures with Lennox-Gastaut syndrome and Dravet syndrome.
September 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30036938/brca1-interacting-protein-cobra1-facilitates-adaptation-to-castrate-resistant-growth-conditions
#4
Huiyoung Yun, Roble Bedolla, Aaron Horning, Rong Li, Huai-Chin Chiang, Tim-H Huang, Robert Reddick, Aria F Olumi, Rita Ghosh, Addanki P Kumar
COBRA1 (co-factor of BRCA1) is one of the four subunits of the negative elongation factor originally identified as a BRCA1-interacting protein. Here, we provide first-time evidence for the oncogenic role of COBRA1 in prostate pathogenesis. COBRA1 is aberrantly expressed in prostate tumors. It positively influences androgen receptor (AR) target gene expression and promoter activity. Depletion of COBRA1 leads to decreased cell viability, proliferation, and anchorage-independent growth in prostate cancer cell lines...
July 20, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/30036348/baricitinib-olumiant-for-rheumatoid-arthritis
#5
(no author information available yet)
No abstract text is available yet for this article.
July 16, 2018: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/29687421/baricitinib-a-review-in-rheumatoid-arthritis
#6
Zaina T Al-Salama, Lesley J Scott
Baricitinib (Olumiant® ) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). This novel, small molecule is approved for use as monotherapy, or in combination with methotrexate, for the treatment of adults with moderate to severe active RA who responded inadequately to or were intolerant of ≥ 1 DMARD. In pivotal multinational trials, once-daily baricitinib 4 mg, with/without methotrexate (± another csDMARD), improved the signs and symptoms of RA, disease activity and physical function in DMARD-naive patients and in patients with an inadequate response to methotrexate, csDMARDs or TNF inhibitors; baricitinib treatment also slowed structural joint damage in DMARD-naive patients and in those with an inadequate response to methotrexate and csDMARDs...
May 2018: Drugs
https://www.readbyqxmd.com/read/29581441/metabolomic-prediction-of-human-prostate-cancer-aggressiveness-magnetic-resonance-spectroscopy-of-histologically-benign-tissue
#7
Lindsey A Vandergrift, Emily A Decelle, Johannes Kurth, Shulin Wu, Taylor L Fuss, Elita M DeFeo, Elkan F Halpern, Matthias Taupitz, W Scott McDougal, Aria F Olumi, Chin-Lee Wu, Leo L Cheng
Prostate cancer alters cellular metabolism through events potentially preceding cancer morphological formation. Magnetic resonance spectroscopy (MRS)-based metabolomics of histologically-benign tissues from cancerous prostates can predict disease aggressiveness, offering clinically-translatable prognostic information. This retrospective study of 185 patients (2002-2009) included prostate tissues from prostatectomies (n = 365), benign prostatic hyperplasia (BPH) (n = 15), and biopsy cores from cancer-negative patients (n = 14)...
March 26, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29511347/parp-1-inhibition-with-or-without-ionizing-radiation-confers-reactive-oxygen-species-mediated-cytotoxicity-preferentially-to-cancer-cells-with-mutant-tp53
#8
Qi Liu, Liliana Gheorghiu, Michael Drumm, Rebecca Clayman, Alec Eidelman, Matthew F Wszolek, Aria Olumi, Adam Feldman, Meng Wang, Lynnette Marcar, Deborah E Citrin, Chin-Lee Wu, Cyril H Benes, Jason A Efstathiou, Henning Willers
Biomarkers and mechanisms of poly (ADP-ribose) polymerase (PARP) inhibitor-mediated cytotoxicity in tumor cells lacking a BRCA-mutant or BRCA-like phenotype are poorly defined. We sought to explore the utility of PARP-1 inhibitor (PARPi) treatment with/without ionizing radiation in muscle-invasive bladder cancer (MIBC), which has poor therapeutic outcomes. We assessed the DNA damaging and cytotoxic effects of the PARPi olaparib in nine bladder cancer cell lines. Olaparib radiosensitized all cell lines with dose enhancement factors from 1...
May 2018: Oncogene
https://www.readbyqxmd.com/read/29502174/baricitinib-for-previously-treated-moderate-or-severe-rheumatoid-arthritis-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#9
REVIEW
Shijie Ren, Iñigo Bermejo, Emma Simpson, Ruth Wong, David L Scott, Adam Young, Matt Stevenson
As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer (Eli Lilly) of baricitinib (BARI; Olumiant® ; a Janus kinase inhibitor that is taken orally) to submit evidence of its clinical and cost effectiveness for the treatment of moderate to severe rheumatoid arthritis (RA) after the failure of disease-modifying antirheumatic drugs (DMARDs). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG)...
July 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29472585/estradiol-signaling-mediates-gender-difference-in-visceral-adiposity-via-autophagy
#10
Zhipeng Tao, Louise D Zheng, Cayleen Smith, Jing Luo, Alex Robinson, Fabio A Almeida, Zongwei Wang, Aria F Olumi, Dongmin Liu, Zhiyong Cheng
Excessive adiposity (particularly visceral fat mass) increases the risks of developing metabolic syndrome. Women have lower deposit of visceral fat than men, and this pattern becomes diminished postmenopausally, but the underlying mechanism remains largely unknown. Here, we show that the gender difference in visceral fat distribution is controlled by an estradiol-autophagy axis. In C57BL/6J and wild-type control mice, a higher visceral fat mass was detected in the males than in the females, which was associated with lower expression of estrogen receptor α (ERα) and more active autophagy in males vs...
February 22, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29303414/expression-of-aromatase-in-tumor-related-stroma-is-associated-with-human-bladder-cancer-progression
#11
Shulin Wu, Jianheng Ye, Zongwei Wang, Sharron X Lin, Min Lu, Yingke Liang, Xuejin Zhu, Aria F Olumi, Wei-de Zhong, Chin-Lee Wu
Putative gender differences in bladder cancer (BCa) have been proposed to result from sex hormone influence. Aromatase is the key enzyme catalyzing the conversion of androgens to estrogens which may result in an intratumoral microenviroment with increased estrogen production. In this study, we investigated the expression pattern of aromatase and its association with BCa progression. Tissue samples from 88 BCa patients who underwent cystectomy were obtained. Using immunohistochemistry (IHC), expression of aromatase in tumor epithelium (TE) and tumor related stroma (TS) were evaluated separately, and the association of aromatase expression status with pathologic variables and overall survival (OS) outcome was examined...
March 4, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29117997/metformin-an-antiproliferative-agent-and-methylation-regulator-in-treating-prostatic-disease
#12
Zongwei Wang, Aria F Olumi
Existing drugs that have been used in clinical practice for other purposes can prove useful for reutilization, since much of the safety profile and pharmacokinetics have been completed. Therefore, the drugs can enter clinical practice for a variety of causes with less regulatory burden. Metformin may prove to be such a drug; it may have a role in other diseases, besides the management of diabetes. In this perspective, we provide our findings and understanding of metformin as an alternative way to treat urological abnormal proliferation...
March 1, 2018: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/28940538/androgenic-to-oestrogenic-switch-in-the-human-adult-prostate-gland-is-regulated-by-epigenetic-silencing-of-steroid-5%C3%AE-reductase-2
#13
MULTICENTER STUDY
Zongwei Wang, Libing Hu, Keyan Salari, Seth K Bechis, Rongbin Ge, Shulin Wu, Cyrus Rassoulian, Jonathan Pham, Chin-Lee Wu, Shahin Tabatabaei, Douglas W Strand, Aria F Olumi
Benign prostatic hyperplasia is the most common proliferative abnormality of the prostate. All men experience some prostatic growth as they age, but the rate of growth varies among individuals. Steroid 5α-reductase 2 (SRD5A2) is a critical enzyme for prostatic development and growth. Previous work indicates that one-third of adult prostatic samples do not express SRD5A2, secondary to epigenetic modifications. Here we show that the level of oestradiol is dramatically elevated, concomitant with significant upregulation of oestrogen response genes, in prostatic samples with methylation at the SRD5A2 promoter...
December 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28882850/two-new-drugs-for-rheumatoid-arthritis
#14
REVIEW
(no author information available yet)
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease that causes inflammation and destruction of the joints.1-3 It can also affect the eyes, the heart and the lungs and is associated with significant disability and increased mortality. RA is estimated to affect just under 1% of the population aged over 16 years, equating to more than 400,000 people in the UK.4 ▼Baricitinib (Olumiant) and ▼tofacitinib (Xeljanz) were launched in the UK in April 2017 and represent a new therapeutic class of medicines known as targeted synthetic disease modifying antirheumatic drugs...
September 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28864223/risk-factors-for-disease-progression-after-postprostatectomy-salvage-radiation-long-term-results-of-a-single-institution-experience
#15
Danielle Rodin, Michael Drumm, Rebecca Clayman, Daniela L Buscariollo, Sigolene Galland-Girodet, Alec Eidelman, Adam S Feldman, Douglas M Dahl, Francis J McGovern, Aria F Olumi, Andrzej Niemierko, William U Shipley, Anthony L Zietman, Jason A Efstathiou
BACKGROUND: Salvage radiotherapy (SRT) has been successfully used for recurrent prostate cancer after radical prostatectomy; however, the optimal timing of SRT remains controversial. Our objective was to identify the risk factors for disease progression after SRT, with a focus on the pre-SRT prostate-specific antigen (PSA) levels in the modern era of PSA testing. PATIENTS AND METHODS: We performed a retrospective review of 551 consecutive patients who had undergone postradical prostatectomy SRT for recurrent prostate cancer from 2000 to 2013...
August 3, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28542736/understanding-temporal-trends-in-medical-costs-associated-with-progression-to-metastatic-prostate-cancer
#16
Daniel M Frendl, Aria F Olumi
No abstract text is available yet for this article.
May 23, 2017: Cancer
https://www.readbyqxmd.com/read/28290136/baricitinib-first-global-approval
#17
REVIEW
Anthony Markham
Baricitinib (Olumiant™) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus. JAKs transduce intracellular signals from cell surface receptors for various cytokines and growth factors involved in inflammation and immune function, suggesting JAK inhibitors may be of therapeutic benefit in inflammatory conditions. In February 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)...
April 2017: Drugs
https://www.readbyqxmd.com/read/28274403/long-term-results-of-adjuvant-versus-early-salvage-postprostatectomy-radiation-a-large-single-institutional-experience
#18
COMPARATIVE STUDY
Daniela L Buscariollo, Michael Drumm, Andrzej Niemierko, Rebecca H Clayman, Sigolene Galland-Girodet, Danielle Rodin, Adam S Feldman, Douglas M Dahl, Francis J McGovern, Aria F Olumi, Alec Eidelman, William U Shipley, Anthony L Zietman, Jason A Efstathiou
PURPOSE: The purpose of this study was to evaluate freedom from biochemical failure (FFBF), freedom from androgen deprivation therapy (FFADT), freedom from distant metastases (FFDM), and overall survival (OS) after adjuvant radiation therapy (ART) versus early salvage radiation therapy (ESRT) in men with prostate cancer and adverse pathologic features (pT3 and/or positive surgical margins). METHODS AND MATERIALS: Of 718 patients consecutively treated with postoperative radiation therapy (RT) for prostate cancer between 1992 and 2013, we retrospectively identified 171 men receiving ART and 230 receiving ESRT (RT delivered at a prostate-specific antigen level ≤0...
March 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28253329/metformin-inhibits-the-proliferation-of-benign-prostatic-epithelial-cells
#19
Zongwei Wang, Xingyuan Xiao, Rongbin Ge, Jijun Li, Cameron W Johnson, Cyrus Rassoulian, Aria F Olumi
OBJECTIVE: Benign prostatic hyperplasia (BPH) is the most common proliferative abnormality of the prostate affecting elderly men throughout the world. Epidemiologic studies have shown that diabetes significantly increases the risk of developing BPH, although whether anti-diabetic medications preventing the development of BPH remains to be defined. We have previously found that stromally expressed insulin-like growth factor 1 (IGF-1) promotes benign prostatic epithelial cell proliferation through paracrine mechanisms...
2017: PloS One
https://www.readbyqxmd.com/read/28002797/targeted-exome-sequencing-reveals-distinct-pathogenic-variants-in-iranians-with-colorectal-cancer
#20
Hassan Ashktorab, Pooneh Mokarram, Hamed Azimi, Hasti Olumi, Sudhir Varma, Michael L Nickerson, Hassan Brim
PURPOSE: Next Generation Sequencing (NGS) is currently used to establish mutational profiles in many multigene diseases such as colorectal cancer (CRC), which is on the rise in many parts of the developing World including, Iran. Little is known about its genetic hallmarks in these populations. AIM: To identify variants in 15 CRC-associated genes in patients of Iranian descent. RESULTS: There were 51 validated variants distributed on 12 genes: 22% MSH3 (n = 11/51), 10% MSH6 (n = 5/51), 8% AMER1 (n = 4/51), 20% APC (n = 10/51), 2% BRAF (n = 1/51), 2% KRAS (n = 1/51), 12% PIK3CA (n = 6/51), 8% TGFβR2A (n = 4/51), 2% SMAD4 (n = 1/51), 4% SOX9 (n = 2/51), 6% TCF7L2 (n = 3/51), and 6% TP53 (n = 3/51)...
January 31, 2017: Oncotarget
keyword
keyword
161243
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"